VIKING THERAPEUTICS INC
VKTXNASDAQ🏆 #1607 by market capEarnings Feb 10US Equity
$26.47▲ $1.11 (+4.36%)
Latest quoteTrack VKTX
Get earnings, price moves & breaking news on Telegram
24h▲ 4.4%
7d▲ 2.5%
14d▼ 3.4%
30d▼ 16.8%
ytd▼ 24.8%
1y▼ 24.8%
🏦Market Cap
$3.37B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
VIKING THERAPEUTICS INC
VKTXAnalyst Ratings
Price
$26.47
Total
24
Raised
0
Lowered
0
Avg PT
$87.17
H / L
$120 / $34
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Canaccord Genuity | Reiterated | Buy | 2026-10-20 | $107.00 | +304.30% |
Truist Securities | Reiterated | Buy | 2026-10-07 | — | — |
JP Morgan | Reiterated | Overweight | 2026-08-11 | — | — |
BTIG | Reiterated | Buy | 2026-05-01 | $125.00 | +372.30% |
Cantor Fitzgerald | Reiterated | Overweight | 2026-04-30 | $100.00 | +277.90% |
HC Wainwright & Co. | Reiterated | Buy | 2026-03-23 | — | — |
Morgan Stanley | Reiterated | Overweight | 2025-10-23 | $95.00 | +259.00% |
Citigroup | Reiterated | Neutral | 2025-07-24 | — | — |
Raymond James | Reiterated | Strong Buy | 2025-07-24 | $116.00 | +338.30% |
B. Riley Securities | Reiterated | Buy | 2025-02-07 | — | — |
Maxim Group | Reiterated | Buy | 2025-02-07 | $15.00 | −43.30% |
Piper Sandler | Reiterated | Overweight | 2025-02-06 | $74.00 | +179.60% |
Oppenheimer | Reiterated | Outperform | 2024-09-25 | $120.00 | +353.40% |
Stifel | Reiterated | Buy | 2024-03-15 | — | — |
Roth MKM | Reiterated | Buy | 2023-05-03 | — | — |
SVB Leerink | Reiterated | Outperform | 2022-04-28 | — | — |
Chardan Capital | Reiterated | Buy | 2020-08-31 | — | — |
BMO Capital | Reiterated | Outperform | 2020-06-05 | — | — |
B. Riley FBR | Reiterated | Buy | 2020-05-04 | — | — |
H.C. Wainwright | Reiterated | Buy | 2020-02-27 | $90.00 | +240.10% |
Stifel Nicolaus | Reiterated | Buy | 2019-06-25 | $95.00 | +259.00% |
SunTrust Robinson Humphrey | Reiterated | Buy | 2018-07-20 | — | — |
William Blair | Reiterated | Outperform | 2018-04-30 | — | — |
Roth Capital | Reiterated | Buy | 2017-11-21 | — | — |
Institution
Canaccord Genuity
Reiterated · Buy · 2026-10-20
$107.00
+304.30%
Truist Securities
Reiterated · Buy · 2026-10-07
—
—
JP Morgan
Reiterated · Overweight · 2026-08-11
—
—
BTIG
Reiterated · Buy · 2026-05-01
$125.00
+372.30%
Cantor Fitzgerald
Reiterated · Overweight · 2026-04-30
$100.00
+277.90%
HC Wainwright & Co.
Reiterated · Buy · 2026-03-23
—
—
Morgan Stanley
Reiterated · Overweight · 2025-10-23
$95.00
+259.00%
Citigroup
Reiterated · Neutral · 2025-07-24
—
—
Raymond James
Reiterated · Strong Buy · 2025-07-24
$116.00
+338.30%
B. Riley Securities
Reiterated · Buy · 2025-02-07
—
—
Maxim Group
Reiterated · Buy · 2025-02-07
$15.00
−43.30%
Piper Sandler
Reiterated · Overweight · 2025-02-06
$74.00
+179.60%
Oppenheimer
Reiterated · Outperform · 2024-09-25
$120.00
+353.40%
Stifel
Reiterated · Buy · 2024-03-15
—
—
Roth MKM
Reiterated · Buy · 2023-05-03
—
—
SVB Leerink
Reiterated · Outperform · 2022-04-28
—
—
Chardan Capital
Reiterated · Buy · 2020-08-31
—
—
BMO Capital
Reiterated · Outperform · 2020-06-05
—
—
B. Riley FBR
Reiterated · Buy · 2020-05-04
—
—
H.C. Wainwright
Reiterated · Buy · 2020-02-27
$90.00
+240.10%
Stifel Nicolaus
Reiterated · Buy · 2019-06-25
$95.00
+259.00%
SunTrust Robinson Humphrey
Reiterated · Buy · 2018-07-20
—
—
William Blair
Reiterated · Outperform · 2018-04-30
—
—
Roth Capital
Reiterated · Buy · 2017-11-21
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space